Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) insider Dennis Cho sold 272 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total transaction of $10,180.96. Following the transaction, the insider now directly owns 81,456 shares in the company, valued at $3,048,898.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Twist Bioscience Trading Down 1.1 %
Shares of NASDAQ TWST opened at $37.57 on Friday. Twist Bioscience Co. has a 1 year low of $11.46 and a 1 year high of $43.21. The company’s 50-day moving average is $36.60 and its 200 day moving average is $27.60.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings data on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.03. Twist Bioscience had a negative return on equity of 32.16% and a negative net margin of 78.44%. The business had revenue of $71.50 million for the quarter, compared to analysts’ expectations of $67.59 million. During the same period in the previous year, the firm posted ($0.74) EPS. The business’s revenue was up 31.8% on a year-over-year basis. On average, research analysts anticipate that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.
Hedge Funds Weigh In On Twist Bioscience
Analyst Ratings Changes
TWST has been the topic of several recent research reports. Scotiabank increased their target price on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a “sector outperform” rating in a report on Monday, February 5th. Barclays upped their price objective on shares of Twist Bioscience from $30.00 to $45.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Finally, The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and raised their target price for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th.
View Our Latest Analysis on TWST
Twist Bioscience Company Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
See Also
- Five stocks we like better than Twist Bioscience
- Pros And Cons Of Monthly Dividend Stocks
- MarketBeat Week in Review – 3/4 – 3/8
- High Flyers: 3 Natural Gas Stocks for March 2022
- What is a Microcap Stock? Everything You Need to Know
- 10 Best Airline Stocks to Buy
- How to Invest in Casino Stocks: Pros and Cons and More
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.